This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker (SYK) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure raises a concern.
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
The Zacks Analyst Blog Highlights: Comcast, Coca-Cola, Bristol-Myers Squibb, Cisco Systems and Stryker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Coca-Cola, Bristol-Myers Squibb, Cisco Systems and Stryker
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 6.13% and 4.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Top Analyst Reports for Comcast, Coca-Cola & Bristol-Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), The Coca-Cola Company (KO), and Bristol-Myers Squibb (BMY).
Why Earnings Season Could Be Great for Stryker (SYK)
by Zacks Equity Research
Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Stryker (SYK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio
by Zacks Equity Research
Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.
PHG or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PHG vs. SYK: Which Stock Is the Better Value Option?
Top Research Reports for Microsoft, Nike & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), NIKE (NKE), and BlackRock (BLK).
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises a concern.
PAHC vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Why Is Stryker (SYK) Down 2.8% Since Last Earnings Report?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
Innovation Drives Robotic-Assisted Surgery: 5 Stocks to Watch
by Sreoshi Bera
Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.
Should You Buy Stryker (SYK) Ahead of Earnings?
by Zacks Equity Research
Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources